Naber CK, Pyxaras SA, Nef H, Ijsselmuiden AJ, Briguori C, Schlundt C, Wykrzykowska J, Eberli FR, Moellmann H, Galatius S, Rieber J, Commeau P, Van Geuns RJ, Bouchez D, Mudra H (2016)
Publication Type: Journal article
Publication year: 2016
Book Volume: 12
Pages Range: 356-8
Journal Issue: 3
DOI: 10.4244/EIJY15M06_02
AIMS: We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice. METHODS AND RESULTS: The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%). CONCLUSIONS: The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.
APA:
Naber, C.K., Pyxaras, S.A., Nef, H., Ijsselmuiden, A.J., Briguori, C., Schlundt, C.,... Mudra, H. (2016). Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study. EuroIntervention, 12(3), 356-8. https://doi.org/10.4244/EIJY15M06_02
MLA:
Naber, Christoph K., et al. "Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study." EuroIntervention 12.3 (2016): 356-8.
BibTeX: Download